A novel artificial intelligence and biosensor device has been developed to monitor if live cancer cells remain after chemotherapy treatment.
In this interview, Stephanie Traub (Cancer Research UK; London, UK) discusses her work as a biomarker specialist and the challenges she faces when developing biomarker strategies.
An isobaric labeling technique has been developed to amplify signals for comprehensive quantitative phosphoproteomic characterization of small cells populations.
A prototype wearable device has been developed to continuously collect live cancer cells directly from a patient’s blood, presenting an alternative to biopsies.
Researchers have discovered a difference between radiation-sensitive and radiation-resistant tumors that could be utilized to assess tumor response, potentially sparing some patients of the toxic side effects of ineffective radiation therapy.
A new microfluidics device has been developed that could detect individual cancer cells in blood and has the potential to be used for liquid biopsies.
Researchers have developed a new diagnostic technique to accurately differentiate bladder cancer from benign inflammation using AHNAK2 protein biomarkers.
Researchers from Syracuse University (NY, USA) have developed a novel class of nanobiosensor that could detect, characterize and analyze protein–protein interactions in blood serum to assist in cancer detection.
Researchers from the University of Queensland (Australia) have discovered a unique biomarker common to multiple cancers that has the potential to change the way early stage cancer is diagnosed.
Researchers at the Brigham Young University (London, UK) have developed a non-invasive, nanoPOTS method for monitoring cancer by measuring the proteins in circulating tumor cells from the blood.